Human telomerase reverse transcriptase expression in ovarian tumors

Awadh Ali Maraei, Ahmad Hatta, Mohd Shiran, Geok Chin Tan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background : Ovarian cancer is the 6 th most common cancer among women. In ovarian tumors, the borderline category is not well defined due to the difficulty in assessing stromal invasion. The World Health Organization (WHO) defined it as tumor that lacks obvious invasion of the stroma with mitotic activity and nuclear abnormalities intermediate between clearly benign and unquestionably malignant. Telomerase is expressed in many human cancers and is hence a potential biomarker for cancer. Immunohistochemical study of anti-human telomerase enzyme reverse transcriptase (hTERT) antibody allows direct visualization of its expression. The aim of this study was to determine the expression of hTERT and serum CA-125 level in ovarian epithelial tumors, and their ability to distinguish borderline tumor from malignancy. Materials and Methods : This was a retrospective study on 68 ovarian epithelial tumors, comprising of 41 cystadenocarcinoma, 22 borderline tumor and five cystadenoma. By immunohistochemistry, hTERT expression was graded as negative (0-10%), focal (11-25%), regional (26-75%) and diffuse (>75%) positivity. Results : hTERT protein expression in ovarian cystadenocarcinoma, borderline tumor and cystadenoma were 71.4%, 59.1% and 0%, respectively. hTERT and CA-125 had a linear relationship with tumor grade and stage. hTERT protein is detected as large granules/speckled in the cytoplasm and nuclei of ovarian tumors. Conclusions : hTERT protein was highly expression in ovarian epithelial carcinoma. However, the difference between carcinoma and borderline tumor was not statistically significant (P-value = 0.51). It is not an independent biomarker to differentiate borderline tumor from malignant tumor. We suggest using the combination of hTERT immunohistochemistry and serum CA-125 to evaluate difficult situations where histological evaluation fails to distinguish malignant from borderline ovarian tumor.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalIndian Journal of Pathology and Microbiology
Volume55
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Neoplasms
Enzymes
Cystadenocarcinoma
Cystadenoma
human TERT protein
Immunohistochemistry
Carcinoma
Proteins
Telomerase
Tumor Biomarkers
Serum
Ovarian Neoplasms
Cytoplasm
Retrospective Studies
Biomarkers
Antibodies

Keywords

  • Borderline ovarian tumor
  • CA-125
  • hTERT
  • immunohistochemistry
  • ovary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)

Cite this

Human telomerase reverse transcriptase expression in ovarian tumors. / Maraei, Awadh Ali; Hatta, Ahmad; Shiran, Mohd; Tan, Geok Chin.

In: Indian Journal of Pathology and Microbiology, Vol. 55, No. 2, 04.2012, p. 187-191.

Research output: Contribution to journalArticle

Maraei, Awadh Ali ; Hatta, Ahmad ; Shiran, Mohd ; Tan, Geok Chin. / Human telomerase reverse transcriptase expression in ovarian tumors. In: Indian Journal of Pathology and Microbiology. 2012 ; Vol. 55, No. 2. pp. 187-191.
@article{6ccf72534d504d01992a09f9f535881d,
title = "Human telomerase reverse transcriptase expression in ovarian tumors",
abstract = "Background : Ovarian cancer is the 6 th most common cancer among women. In ovarian tumors, the borderline category is not well defined due to the difficulty in assessing stromal invasion. The World Health Organization (WHO) defined it as tumor that lacks obvious invasion of the stroma with mitotic activity and nuclear abnormalities intermediate between clearly benign and unquestionably malignant. Telomerase is expressed in many human cancers and is hence a potential biomarker for cancer. Immunohistochemical study of anti-human telomerase enzyme reverse transcriptase (hTERT) antibody allows direct visualization of its expression. The aim of this study was to determine the expression of hTERT and serum CA-125 level in ovarian epithelial tumors, and their ability to distinguish borderline tumor from malignancy. Materials and Methods : This was a retrospective study on 68 ovarian epithelial tumors, comprising of 41 cystadenocarcinoma, 22 borderline tumor and five cystadenoma. By immunohistochemistry, hTERT expression was graded as negative (0-10{\%}), focal (11-25{\%}), regional (26-75{\%}) and diffuse (>75{\%}) positivity. Results : hTERT protein expression in ovarian cystadenocarcinoma, borderline tumor and cystadenoma were 71.4{\%}, 59.1{\%} and 0{\%}, respectively. hTERT and CA-125 had a linear relationship with tumor grade and stage. hTERT protein is detected as large granules/speckled in the cytoplasm and nuclei of ovarian tumors. Conclusions : hTERT protein was highly expression in ovarian epithelial carcinoma. However, the difference between carcinoma and borderline tumor was not statistically significant (P-value = 0.51). It is not an independent biomarker to differentiate borderline tumor from malignant tumor. We suggest using the combination of hTERT immunohistochemistry and serum CA-125 to evaluate difficult situations where histological evaluation fails to distinguish malignant from borderline ovarian tumor.",
keywords = "Borderline ovarian tumor, CA-125, hTERT, immunohistochemistry, ovary",
author = "Maraei, {Awadh Ali} and Ahmad Hatta and Mohd Shiran and Tan, {Geok Chin}",
year = "2012",
month = "4",
doi = "10.4103/0377-4929.97865",
language = "English",
volume = "55",
pages = "187--191",
journal = "Indian Journal of Pathology and Microbiology",
issn = "0377-4929",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Human telomerase reverse transcriptase expression in ovarian tumors

AU - Maraei, Awadh Ali

AU - Hatta, Ahmad

AU - Shiran, Mohd

AU - Tan, Geok Chin

PY - 2012/4

Y1 - 2012/4

N2 - Background : Ovarian cancer is the 6 th most common cancer among women. In ovarian tumors, the borderline category is not well defined due to the difficulty in assessing stromal invasion. The World Health Organization (WHO) defined it as tumor that lacks obvious invasion of the stroma with mitotic activity and nuclear abnormalities intermediate between clearly benign and unquestionably malignant. Telomerase is expressed in many human cancers and is hence a potential biomarker for cancer. Immunohistochemical study of anti-human telomerase enzyme reverse transcriptase (hTERT) antibody allows direct visualization of its expression. The aim of this study was to determine the expression of hTERT and serum CA-125 level in ovarian epithelial tumors, and their ability to distinguish borderline tumor from malignancy. Materials and Methods : This was a retrospective study on 68 ovarian epithelial tumors, comprising of 41 cystadenocarcinoma, 22 borderline tumor and five cystadenoma. By immunohistochemistry, hTERT expression was graded as negative (0-10%), focal (11-25%), regional (26-75%) and diffuse (>75%) positivity. Results : hTERT protein expression in ovarian cystadenocarcinoma, borderline tumor and cystadenoma were 71.4%, 59.1% and 0%, respectively. hTERT and CA-125 had a linear relationship with tumor grade and stage. hTERT protein is detected as large granules/speckled in the cytoplasm and nuclei of ovarian tumors. Conclusions : hTERT protein was highly expression in ovarian epithelial carcinoma. However, the difference between carcinoma and borderline tumor was not statistically significant (P-value = 0.51). It is not an independent biomarker to differentiate borderline tumor from malignant tumor. We suggest using the combination of hTERT immunohistochemistry and serum CA-125 to evaluate difficult situations where histological evaluation fails to distinguish malignant from borderline ovarian tumor.

AB - Background : Ovarian cancer is the 6 th most common cancer among women. In ovarian tumors, the borderline category is not well defined due to the difficulty in assessing stromal invasion. The World Health Organization (WHO) defined it as tumor that lacks obvious invasion of the stroma with mitotic activity and nuclear abnormalities intermediate between clearly benign and unquestionably malignant. Telomerase is expressed in many human cancers and is hence a potential biomarker for cancer. Immunohistochemical study of anti-human telomerase enzyme reverse transcriptase (hTERT) antibody allows direct visualization of its expression. The aim of this study was to determine the expression of hTERT and serum CA-125 level in ovarian epithelial tumors, and their ability to distinguish borderline tumor from malignancy. Materials and Methods : This was a retrospective study on 68 ovarian epithelial tumors, comprising of 41 cystadenocarcinoma, 22 borderline tumor and five cystadenoma. By immunohistochemistry, hTERT expression was graded as negative (0-10%), focal (11-25%), regional (26-75%) and diffuse (>75%) positivity. Results : hTERT protein expression in ovarian cystadenocarcinoma, borderline tumor and cystadenoma were 71.4%, 59.1% and 0%, respectively. hTERT and CA-125 had a linear relationship with tumor grade and stage. hTERT protein is detected as large granules/speckled in the cytoplasm and nuclei of ovarian tumors. Conclusions : hTERT protein was highly expression in ovarian epithelial carcinoma. However, the difference between carcinoma and borderline tumor was not statistically significant (P-value = 0.51). It is not an independent biomarker to differentiate borderline tumor from malignant tumor. We suggest using the combination of hTERT immunohistochemistry and serum CA-125 to evaluate difficult situations where histological evaluation fails to distinguish malignant from borderline ovarian tumor.

KW - Borderline ovarian tumor

KW - CA-125

KW - hTERT

KW - immunohistochemistry

KW - ovary

UR - http://www.scopus.com/inward/record.url?scp=84863760884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863760884&partnerID=8YFLogxK

U2 - 10.4103/0377-4929.97865

DO - 10.4103/0377-4929.97865

M3 - Article

C2 - 22771641

AN - SCOPUS:84863760884

VL - 55

SP - 187

EP - 191

JO - Indian Journal of Pathology and Microbiology

JF - Indian Journal of Pathology and Microbiology

SN - 0377-4929

IS - 2

ER -